Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

Published:2011-06-28 Issue:1 Volume:118 Page:147-156
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Edeline Julien,Boucher Eveline,Rolland Yan,Vauléon Elodie,Pracht Marc,Perrin Christophe,Le Roux Catherine,Raoul Jean-Luc

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.26255/fullpdf

Reference39 articles.

1. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med.,2008

2. Biology of hepatocellular carcinoma;Pang;Ann Surg Oncol.,2008

3. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling;Wilhelm;Mol Cancer Ther.,2008

4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol.,2009

Cited by 244 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecule tyrosine kinase inhibitors approved for systemic therapy of advanced hepatocellular carcinoma: recent advances and future perspectives;Discover Oncology;2024-07-03

2. Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review;Frontiers in Oncology;2024-03-27

3. The Association Between Modified Albumin-Bilirubin (mALBI) and Survival in Advanced Non-small Cell Lung Cancer Patients Treated With Immunotherapy;Cureus;2024-03-13

4. Radiographic and serologic response in patients with unresectable hepatocellular carcinoma receiving systemic antineoplastic treatments: A trial‐level analysis;Cancer;2024-01-17

5. Treatment response assessment to chemotherapy with bevacizumab for colorectal liver metastasis by contrast-enhanced ultrasound;Quantitative Imaging in Medicine and Surgery;2024-01